Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2026 Jan 7;16:1772783. doi: 10.3389/fimmu.2025.1772783

Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer

Lu Zou 1,2,†, Jingjing Chen 1,2,†, Xinyuan Bai 1,2, Yingxin Wang 1,3, Changchang Lu 4, Qiaoli Wang 1, Subiyinuer Tuerhong 1,3, Mengzhu Li 2, Qinghua Zheng 3, Fanyan Meng 1,3,5,*, Juan Du 1,2,*
PMCID: PMC12820721  PMID: 41573566

An incorrect Funding statement was provided. The correct funder is “the National Natural Science Foundation of China (No. 82373280), Key Project supported by Medical Science and technology development Foundation, Nanjing Department of Health (ZKX24021 and YKK24072), the provincial key medical disciplines during the “14th Five-Year Plan” period (ZDXK202233) and 2024 Annual Medical Research Projects of the Jiangsu Provincial Health Commission (K2024038)”.

The original version of this article has been updated.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES